What does SAB Biotherapeutics, Inc. do?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable…
What is SAB Biotherapeutics, Inc.'s P/E and P/B ratio?
SAB Biotherapeutics, Inc. has a P/E ratio of -2.4 and a P/B ratio of 1.29.
What is SAB Biotherapeutics, Inc.'s debt-to-equity ratio?
SAB Biotherapeutics, Inc. has a debt-to-equity ratio of 0.02.
How much does SAB Biotherapeutics, Inc. owe compared with what it owns?
SAB Biotherapeutics, Inc. owes $0.10 for every $1 it owns (balance sheet Jun 2026), which is low.
What is SAB Biotherapeutics, Inc.'s Positivity rank?
SAB Biotherapeutics, Inc. is ranked #3,610 of 6,774 companies globally and #1,594 of 4,000 in United States on PositoAI, with a Positivity Score of 20,407.
Does SAB Biotherapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for SAB Biotherapeutics, Inc..
Where can I read the latest news about SAB Biotherapeutics, Inc.?
Recent headlines about SAB Biotherapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does SAB Biotherapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of SAB Biotherapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.